Platelet and Extracellular Vesicles in COVID-19 Infection and Its Vaccines

Overview

Journal Transfus Apher Sci

Specialty Hematology

Date 2022 Jun 2

PMID 35654711

Authors

Hadi Goubran

Jerard Seghatchian

Waleed Sabry

Gaafar Ragab

Thierry Burnouf

Affiliations

Soon will be listed here.

Abstract

Platelets are at the crossroads between thrombosis and inflammation. When activated, platelets can shed bioactive extracellular vesicles [pEVs] that share the hemostatic potential of their parent cells and act as bioactive shuttles of their granular contents. In a viral infection, platelets are activated, and pEVs are generated with occasional virion integration. Both platelets and pEVs are engaged in a bidirectional interaction with neutrophils and other cells of the immune system and the hemostatic pathways. Severe COVID-19 infection is characterized by a stormy thromboinflammatory response with platelets and their EVs at the center stage of this reaction. This review sheds light on the interactions of platelets, pEVS and SARS-CoV-2 infection and prognostic and potential therapeutic role of pEVs. The review also describes the role of pEVs in the rare adenovirus-based COVID-19 vaccine-induced thrombosis thrombocytopenia.

Citing Articles

Flow cytometry for extracellular vesicle characterization in COVID-19 and post-acute sequelae of SARS-CoV-2 infection.

Fanelli M, Petrone V, Chirico R, Radu C, Minutolo A, Matteucci C Extracell Vesicles Circ Nucl Acids. 2024; 5(3):417-437.

PMID: 39697632 PMC: 11648478. DOI: 10.20517/evcna.2024.20.

Immunothrombosis: A bibliometric analysis from 2003 to 2023.

Hou M, Wu J, Li J, Zhang M, Yin H, Chen J Medicine (Baltimore). 2024; 103(37):e39566.

PMID: 39287275 PMC: 11404911. DOI: 10.1097/MD.0000000000039566.

Bioprocessing of human platelet concentrates to generate lysates and extracellular vesicles for therapeutic applications.

Yeh W, Yu E, Lu Y, Livkisa D, Burnouf T, Lundy D MethodsX. 2024; 13:102822.

PMID: 39105089 PMC: 11299553. DOI: 10.1016/j.mex.2024.102822.

Extracellular Vesicles: The Invisible Heroes and Villains of COVID-19 Central Neuropathology.

Chang H, Chen E, Hu Y, Wu L, Deng L, Ye-Lehmann S Adv Sci (Weinh). 2023; 11(10):e2305554.

PMID: 38143270 PMC: 10933635. DOI: 10.1002/advs.202305554.

Advances in Purification, Modification, and Application of Extracellular Vesicles for Novel Clinical Treatments.

Matsuzaka Y, Yashiro R Membranes (Basel). 2022; 12(12).

PMID: 36557150 PMC: 9787595. DOI: 10.3390/membranes12121244.

References

Deppermann C, Kubes P . Platelets and infection. Semin Immunol. 2016; 28(6):536-545. DOI: 10.1016/j.smim.2016.10.005. View

Rausch L, Lutz K, Schifferer M, Winheim E, Gruber R, Oesterhaus E . Binding of phosphatidylserine-positive microparticles by PBMCs classifies disease severity in COVID-19 patients. J Extracell Vesicles. 2021; 10(14):e12173. PMC: 8636722. DOI: 10.1002/jev2.12173. View

Jy W, Ricci M, Shariatmadar S, Gomez-Marin O, Horstman L, Ahn Y . Microparticles in stored red blood cells as potential mediators of transfusion complications. Transfusion. 2011; 51(4):886-93. PMC: 3095366. DOI: 10.1111/j.1537-2995.2011.03099.x. View

Garnier Y, Claude L, Hermand P, Sachou E, Claes A, Desplan K . Plasma microparticles of intubated COVID-19 patients cause endothelial cell death, neutrophil adhesion and netosis, in a phosphatidylserine-dependent manner. Br J Haematol. 2021; 196(5):1159-1169. DOI: 10.1111/bjh.18019. View

Niu J, Sareli C, Mayer D, Visbal A, Sareli A . Lymphopenia as a Predictor for Adverse Clinical Outcomes in Hospitalized Patients with COVID-19: A Single Center Retrospective Study of 4485 Cases. J Clin Med. 2022; 11(3). PMC: 8837002. DOI: 10.3390/jcm11030700. View

Punyadee N, Mairiang D, Thiemmeca S, Komoltri C, Pan-Ngum W, Chomanee N . Microparticles provide a novel biomarker to predict severe clinical outcomes of dengue virus infection. J Virol. 2014; 89(3):1587-607. PMC: 4300736. DOI: 10.1128/JVI.02207-14. View

Yan Y, Zhou W, Wang Y, Guo Q, Zhao F, Zhu Z . The Potential Role of Extracellular Vesicles in COVID-19 Treatment: Opportunity and Challenge. Front Mol Biosci. 2021; 8:699929. PMC: 8345113. DOI: 10.3389/fmolb.2021.699929. View

Marchandot B, Carmona A, Trimaille A, Curtiaud A, Morel O . Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis. J Thromb Thrombolysis. 2021; 52(3):689-691. PMC: 8204296. DOI: 10.1007/s11239-021-02505-4. View

Ge J, Ma Y, Wu Z, Jin J, Sun X . Anticoagulation treatment for patients with coronavirus disease 2019 (COVID-19) and its clinical effectiveness in 2020: A meta-analysis study. Medicine (Baltimore). 2021; 100(47):e27861. PMC: 8615308. DOI: 10.1097/MD.0000000000027861. View

10.

Boilard E, Pare G, Rousseau M, Cloutier N, Dubuc I, Levesque T . Influenza virus H1N1 activates platelets through FcγRIIA signaling and thrombin generation. Blood. 2014; 123(18):2854-63. DOI: 10.1182/blood-2013-07-515536. View

11.

Rank A, Nieuwland R, Crispin A, Grutzner S, Iberer M, Toth B . Clearance of platelet microparticles in vivo. Platelets. 2011; 22(2):111-6. DOI: 10.3109/09537104.2010.520373. View

12.

Middleton E, He X, Denorme F, Campbell R, Ng D, Salvatore S . Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. 2020; 136(10):1169-1179. PMC: 7472714. DOI: 10.1182/blood.2020007008. View

13.

Bouayad A . HLA and PF4 antibody production after adenoviral vector SARS-CoV-2 vaccination. Curr Res Transl Med. 2021; 69(4):103312. PMC: 8445795. DOI: 10.1016/j.retram.2021.103312. View

14.

Rossaint J, Kuhne K, Skupski J, Van Aken H, Looney M, Hidalgo A . Directed transport of neutrophil-derived extracellular vesicles enables platelet-mediated innate immune response. Nat Commun. 2016; 7:13464. PMC: 5116072. DOI: 10.1038/ncomms13464. View

15.

Goubran H, Burnouf T, Stakiw J, Seghatchian J . Platelet microparticle: a sensitive physiological "fine tuning" balancing factor in health and disease. Transfus Apher Sci. 2015; 52(1):12-8. DOI: 10.1016/j.transci.2014.12.015. View

16.

Nicolai L, Massberg S . Platelets as key players in inflammation and infection. Curr Opin Hematol. 2019; 27(1):34-40. DOI: 10.1097/MOH.0000000000000551. View

17.

Khan S, Kelher M, Heal J, Blumberg N, Boshkov L, Phipps R . Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood. 2006; 108(7):2455-62. PMC: 1895564. DOI: 10.1182/blood-2006-04-017251. View

18.

Goubran H, Stakiw J, Radosevic M, Burnouf T . Platelet-cancer interactions. Semin Thromb Hemost. 2014; 40(3):296-305. DOI: 10.1055/s-0034-1370767. View

19.

Rolla R, Puricelli C, Bertoni A, Boggio E, Gigliotti C, Chiocchetti A . Platelets: "multiple choice" effectors in the immune response and their implication in COVID-19 thromboinflammatory process. Int J Lab Hematol. 2021; 43(5):895-906. PMC: 8251141. DOI: 10.1111/ijlh.13516. View

20.

Assinger A . Platelets and infection - an emerging role of platelets in viral infection. Front Immunol. 2015; 5:649. PMC: 4270245. DOI: 10.3389/fimmu.2014.00649. View